{
  "docId": "019de076-f846-767d-9b7f-8682a04c3e89",
  "docSlug": "d28195e1bb64bc51ad898953c5c30263",
  "documentTitle": "Boundless Bio | IPO Presentation Deck | 51 slides",
  "authorId": "boundless-bio",
  "authorName": "Boundless Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 12,
  "pageCount": 51,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "pain_points",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide uses a color-coded matrix to illustrate clinical failure or limited efficacy in amplified tumors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f846-767d-9b7f-8682a04c3e89/12",
  "deckHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89",
  "deckJsonHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89.json",
  "deckAnchorHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.85
      },
      "kind": "callout",
      "text": "With the exception of HER2, targeted therapies have not been approved for, nor demonstrated robust clinical activity in, most oncogene amplified cancers",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d918fba8-b6bc-46cb-a2bf-c0955dee8f55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Heatmap matrix of oncogenes vs cancer types with ORR metrics",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "638bfbab-15a7-49a4-9beb-5a4f3b8dc7ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "ORR: overall response rate; NSCLC: non-small cell lung cancer; *17% ORR reflects exclusion of HER2+ breast, gastric, and colorectal cancers",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "695e8b97-130c-4e88-aa50-4a288b5644ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "legend",
      "text": "Color legend for activity levels: Red (Failed), Yellow (Limited), Grey (Not tested), Orange (Approval in combo), Green (Approval for overexpression)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "814a649e-0278-420e-b1c9-5c1f89bb7fc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Across most oncogenes, patients with gene amplified tumors derive little benefit from targeted therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d54ae82-2fc3-4218-b077-c56288595bdc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "ab075a6d-e26b-4cce-9d93-83c767ad7062",
      "evidence": "The heatmap matrix could be interpreted as a 2x2 matrix, although it's not a traditional 2x2 matrix.",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "heatmap-matrix",
      "slug": null,
      "matchId": "626cb809-69c3-487c-947b-83563299b420",
      "evidence": "The slide uses a grid to map oncogenes against cancer types with color-coded status indicators.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 13,
      "from": 10,
      "beatId": "4b153014-3605-47f4-a47a-aafe591b86d2",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document highlights the challenges of treating cancers with oncogene amplifications and the need for new therapeutic approaches",
      "position": 1,
      "confidence": 0.9,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4f4eed56-ecab-4444-af8a-18249787c591",
      "evidence": "The document highlights the limitations of current treatments and the need for new therapeutic approaches",
      "position": 0,
      "objective": "What is the cost of not addressing oncogene amplified cancers?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}